Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2021-10-13 Regulatory Filings
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Other.pdf
Regulatory Filings
2021-10-13 English
Other.pdf
Merger & Acquisition Classification · 100% confidence The document is a Letter of Transmittal related to a corporate acquisition arrangement involving Trillium Therapeutics Inc. and Pfizer Inc. It instructs registered securityholders on how to deposit their shares and warrants to receive consideration under a Plan of Arrangement. The document references an Information Circular dated September 27, 2021, which is the formal disclosure document for the arrangement. The Letter of Transmittal is a procedural document used in mergers and acquisitions to facilitate the exchange of securities for consideration. It is not a financial report, earnings release, or regulatory filing in the usual sense, but rather a transactional document related to a merger/acquisition event. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (15,000 characters) and content confirm it is the actual transmittal letter, not just an announcement or proxy solicitation.
2021-09-27 English
Form of proxy - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'First Supplemental Indenture' and details amendments to a warrant indenture between Elevation Gold Mining Corporation and a warrant agent. It discusses modifications to warrant terms, share consolidation, exercise price adjustments, and includes legal language typical of indenture agreements. There is no financial performance data, earnings information, or management discussion. The document is a legal contract supplementing an existing indenture related to warrants and share reorganization. This fits the category of Capital/Financing Update (CAP), as it relates to changes in capital structure and warrant terms. The document length is substantial and contains the full text of the supplemental indenture, not just an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the appropriate classification is CAP with high confidence.
2021-09-27 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Special Meeting of Shareholders and Warrant Holders for Trillium Therapeutics, Inc., scheduled for October 26, 2021. It details the meeting agenda, voting procedures, record date, proxy instructions, and legal considerations related to a statutory arrangement under the Business Corporations Act (British Columbia). The document is a formal notification to shareholders and warrant holders about the meeting and related voting matters, including references to an Information Circular and other materials. It does not contain financial statements, management discussion, or detailed report content itself. The document is a solicitation for votes and information about the meeting, consistent with a Proxy Solicitation & Information Statement or related notice. However, since it is specifically titled as a "Notice of Special Meeting" and includes proxy and voting instructions, it aligns best with the Proxy Solicitation & Information Statement (PSI) category rather than just a general announcement or regulatory filing. Therefore, the appropriate classification is PSI with high confidence.
2021-09-27 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for corporate actions. It includes detailed information about a special meeting of shareholders and warrant holders to approve a merger arrangement with Pfizer. The document contains a Management Information Circular and Proxy Statement, which are typical materials sent to shareholders to provide information and request votes for meetings. The presence of voting instructions, meeting notices, and detailed descriptions of proposals confirms this is a Proxy Solicitation & Information Statement. It is not an Annual Report, Earnings Release, or other financial report, but rather a solicitation document for shareholder voting.
2021-09-27 English
Other.pdf
Regulatory Filings
2021-09-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.